New somatostatin analogs: Will they fulfil old promises?

European Journal of Endocrinology

Volumn 146, Issue 5, 2002, Pages 701-705

  Lamberts, S W J ^a   van der Lely, A J ^a   Hofland, L J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADENYLATE CYCLASE; AMYLASE; ANGIOPEPTIN; BIM 23244; BIM 23268; BIM 23A387; CYTOTOXIC AGENT; GASTRIN; GLUCAGON; GROWTH HORMONE; GROWTH HORMONE RELEASING FACTOR; GUANINE NUCLEOTIDE BINDING PROTEIN; INSULIN; OCTREOTIDE; PASIREOTIDE; PROLACTIN; RADIOISOTOPE; RECEPTOR SUBTYPE; SEROTONIN; SOMATOMEDIN C RECEPTOR; SOMATOSTATIN; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR; TACHYKININ; TRIACYLGLYCEROL LIPASE; TRYPSIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VAPREOTIDE; VASOACTIVE INTESTINAL POLYPEPTIDE;

ACROMEGALY; ARTICLE; CARCINOID; CONTROLLED STUDY; DEHYDRATION; DIARRHEA; DOSE RESPONSE; DRUG ACTIVITY; DRUG DELIVERY SYSTEM; DRUG HALF LIFE; DRUG INDICATION; DRUG MECHANISM; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SYNTHESIS; ENZYMATIC DEGRADATION; ESOPHAGUS VARICES BLEEDING; GALLBLADDER DISEASE; GALLSTONE FORMATION; GASTROINTESTINAL DISEASE; GROWTH HORMONE RELEASE; HORMONAL REGULATION; HORMONE INHIBITION; HUMAN; HYPOGLYCEMIA; HYPOKALEMIA; MUSCLE CRAMP; NEUROENDOCRINE TUMOR; NONHUMAN; PANCREAS DISEASE; PANCREAS ISLET CELL TUMOR; PEPTIC ULCER; PRIORITY JOURNAL; SKIN DEFECT; SLOW RELEASE FORMULATION; VIPOMA;

EID: 0036106183     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/eje.0.1460701     Document Type: Article

References (30)

1. Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone
2. Clinical applications of somatostatin analogs
3. Somatostatin and its receptor family
4. Peptides in the brain: The new endocrinology of the neuron
5. A very potent and selective octapeptide analogue of somatostatin with prolonged action
6. The somatostatin analog SMS 201-995 induces long-acting inhibition of growth hormone secretion without rebound hypersecretion in acromegalic patients
7. Somatostatin receptors in human endocrine tumors Cancer
8. Long-term treatment of acromegaly with the somatostatin analogue SMS 201-995
9. The role of somatostatin in the regulation of anterior pituitary hormone secretion and the use of its analogs in the treatment of human pituitary tumors
10. Octreotide
11. Localisation of endocrine-related tumours with radioiodinated analogue of somatostatin
12. Somatostatin-receptor imaging in the localization of endocrine tumors
13. 3]octreotide by mouse and human pituitary tumor cells: Increase by unlabeled octreotide
14. Peptide receptor imaging and therapy
15. Cancer chemotherapy based on targeting of cytotoxic peptide conjugates to their receptors on tumors
16. The effect of the somatostatin analog SMS 201-995 on normal growth hormone secretion in the rat. A comparison with the effect of bromocriptine on normal prolactin secretion
17. Diminishing efficacy of octreotide (SMS 201-995) on gastric functions of healthy subjects during one-week administration
18. Effect of somatostatin analogue (SMS 201-995, Sandostatin) on pancreatic secretion in humans
19. Somatostatin receptor subtype specificity in human fetal pituitary cultures. Differential role of SSTR2 and SSTR5 for growth hormone, thyroid-stimulating hormone, and prolactin regulation
20. Somatostatin receptor (SSTR) subtype-selective analogues differentially suppress in vitro growth hormone and prolactin in human pituitary adenomas. Novel potential therapy for functional pituitary tumors
21. Receptors for dopamine and somatostatin: Formation of heterooligomers with enhanced functional activity
22. Subtypes of the somatostatin receptor assemble as functional homo- and heterodimers
23. Functional association of sstr2 and sstr5 in suppression of growth hormone secretion
24. Bim-23244, a somatostatin receptor subtype 2- and 5-selective analog with enhanced efficacy in suppressing growth hormone (GH) from octreotide-resistant human GH-secreting adenomas
25. A new somatostatin peptidomimetic with broad SRIF receptor binding and a unique inhibitory profile
26. Intracellular dynamics of sst5 receptors in transfected COS-7 cells: Maintenance of cell surface receptors during ligand-induced endocytosis
27. Long-acting somatostatin analogue (Sandostatin) reduces late night insulinopenic ketogenesis in diabetic teenagers
28. Effect of long-acting somatostatin analog (Somatulin) on renal hyperfiltration in patients with IDDM
29. Essential role of growth hormone in ischemia-induced retinal neovascularization
30. The efficacy of octreotide in the therapy of severe nonproliferative and early proliferative diabetic retinopathy: A randomized controlled study